Literature DB >> 20437119

Cancer therapies and bone health.

Mimi I Hu1, Huifang Lu, Robert F Gagel.   

Abstract

Cancer patients are at risk for adverse events involving bone. Metastasis of cancer to bone and primary bone tumors can compromise the integrity of bone. Various cancer therapies cause long-term skeletal disorders, particularly bone loss, osteomalacia, and avascular necrosis. Cancer therapies that include chemotherapy, glucocorticoids, hormonal agents, and newer targeted therapies can affect bone in several ways. With the improved effectiveness of cancer treatment, more cancer patients are surviving longer and may experience fractures as a long-term complication of bone loss. Prevention of bone loss through early detection and appropriate use of anti-osteoporosis treatment may decrease bone loss and fractures. This article reviews causative risk factors, mechanisms, and prevention and treatment strategies for cancer therapy-related bone loss in hematologic and specific solid malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437119     DOI: 10.1007/s11926-010-0098-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  63 in total

Review 1.  Toxic effects of cis-dichlorodiammineplatinum(II) in man.

Authors:  D D Von Hoff; R Schilsky; C M Reichert; R L Reddick; M Rozencweig; R C Young; F M Muggia
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

2.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

3.  Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer.

Authors:  S M Pierce; A Recht; T I Lingos; A Abner; F Vicini; B Silver; A Herzog; J R Harris
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

Review 4.  Mechanisms of steroid impairment of growth.

Authors:  Ze'ev Hochberg
Journal:  Horm Res       Date:  2002

5.  Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.

Authors:  Leena Vehmanen; Inkeri Elomaa; Carl Blomqvist; Tiina Saarto
Journal:  J Clin Oncol       Date:  2006-02-01       Impact factor: 44.544

6.  Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.

Authors:  Janet E Brown; Sue P Ellis; Paul Silcocks; Aubrey Blumsohn; Sandra A Gutcher; Clare Radstone; Barry W Hancock; Matthew Q Hatton; Robert E Coleman
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

7.  Adriamycin inhibits PTH-mediated but not PGE2-mediated stimulation of cyclic AMP formation in isolated bone cells.

Authors:  G Kohler; V Shen; W A Peck
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

8.  Nephrotoxicity associated with ifosfamide.

Authors:  J Smeitink; M Verreussel; C Schröder; R Lippens
Journal:  Eur J Pediatr       Date:  1988-11       Impact factor: 3.183

Review 9.  Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Authors:  Terrence H Diamond; Celestia S Higano; Matthew R Smith; Theresa A Guise; Frederick R Singer
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

10.  Reduced bone mineral density in men following chemotherapy for Hodgkin's disease.

Authors:  S J Holmes; R W Whitehouse; S T Clark; D C Crowther; J E Adams; S M Shalet
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more
  3 in total

1.  Comparison of percutaneous vertebroplasty with and without interventional tumor removal for spinal metastatic tumor without epidural involvement.

Authors:  Yan Su; Zhong-Zhen Sun; Long-Xiang Shen; Jian Ding; Zheng-Yu Xu; Yi-Min Chai; Wen-Qi Song; Dong Chen; Chun-Gen Wu
Journal:  J Bone Oncol       Date:  2016-12-23       Impact factor: 4.072

2.  Impact of denosumab on bone mass in cancer patients.

Authors:  Ursa Brown-Glaberman; Alison T Stopeck
Journal:  Clin Pharmacol       Date:  2013-07-04

3.  Medial clavicle fracture with bone destruction after radical neck dissection combined with postoperative chemotherapy for secondary cervical lymph node metastasis of tongue cancer: a case report.

Authors:  Masayasu Tashiro; Tomoaki Sano; Kazutaka Sugiura; Yasuhito Minamida; Yoshihiro Abiko; Hiroki Nagayasu; Eiji Nakayama
Journal:  Oral Radiol       Date:  2021-02-12       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.